Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
454
datasets available to search
ShareScore release 0.9.0
Dataset results
454 results for “Tamoxifen”
PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM)
ClinicalTrials.gov study NCT01192308. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Breast Cancer
ClinicalTrials.gov study NCT00032136. IPD Sharing: Not stated. Countries: 1. Publications: 11.
Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer
ClinicalTrials.gov study NCT00002864. IPD Sharing: NO. Countries: 2. Publications: 3.
A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma
ClinicalTrials.gov study NCT00001436. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Ductal Lavage in Assessing Women With Early Breast Cancer or at High Risk of Developing Breast Cancer and Who Are Eligible For Tamoxifen Therapy
ClinicalTrials.gov study NCT00083044. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Data from: Investigation of discriminant metabolites in tamoxifen-resistant and choline kinase-alpha-downregulated breast cancer cells using 1H-nuclear magnetic resonance spectroscopy
Metabolites linked to changes in choline kinase-α (CK-α) expression and drug resistance, which contribute to survival and autophagy mechanisms, are attractive targets for breast cancer therapies. We previously reported that autophagy played a causative role in driving tamoxifen (TAM) resistance of breast cancer cells (BCCs) and was also promoted by CK-α knockdown, resulting in the survival of TAM-resistant BCCs. There is no comparative study yet about the metabolites resulting from BCCs with TAM-resistance and CK-α knockdown. Therefore, the aim of this study was to explore the discriminant metabolic biomarkers responsible for TAM resistance as well as CK-α expression, which might be linked with autophagy through a protective role. A total of 33 intracellular metabolites, including a range of amino acids, energy metabolism-related molecules and others from cell extracts of the parental cells (MCF-7), TAM-resistant cells (MCF-7/TAM) and CK-α knockdown cells (MCF-7/shCK-α, MCF-7/TAM/shCK-α) were analyzed by proton nuclear magnetic resonance spectroscopy (1H-NMRS). Principal component analysis (PCA) and partial least square discriminant analysis (PLS-DA) revealed the existence of differences in the intracellular metabolites to separate the 4 groups: MCF-7 cells, MCF-7/TAM cells, MCF-7-shCK-α cells, and MCF-7/TAM/shCK-α cells. The metabolites with VIP>1 contributed most to the differentiation of the cell groups, and they included fumarate, UA (unknown A), lactate, myo-inositol, glycine, phosphocholine, UE (unknown E), glutamine, formate, and AXP (AMP/ADP/ATP). Our results suggest that these altered metabolites would be promising metabolic biomarkers for a targeted therapeutic strategy in BCCs that exhibit TAM-resistance and aberrant CK-α expression, which triggers a survival and drug resistance mechanism.
Liver Safety Under Upfront Arimidex vs Tamoxifen
ClinicalTrials.gov study NCT00537771. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer
ClinicalTrials.gov study NCT04504331. IPD Sharing: NO. Countries: 1. Publications: 0.
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
ClinicalTrials.gov study NCT02586675. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
ClinicalTrials.gov study NCT02936206. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study to Evaluate the Effect of Letrozole and Tamoxifen on Bone and Lipids in Postmenopausal Women With Breast Cancer
ClinicalTrials.gov study NCT00171704. IPD Sharing: Not stated. Countries: 2. Publications: 0.
Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer
ClinicalTrials.gov study NCT02668666. IPD Sharing: NO. Countries: 1. Publications: 0.
Randomized Trial Of Exemestane Versus Continued Tamoxifen In Postmenopausal Women With Early Breast Cancer
ClinicalTrials.gov study NCT00038467. IPD Sharing: Not stated. Countries: 37. Publications: 0.
TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer
ClinicalTrials.gov study NCT02988986. IPD Sharing: YES. Countries: 1. Publications: 0.
Study of Estrogen Levels in Premenopausal Women Who Have Undergone Surgery for Breast Cancer and Are Receiving Triptorelin and Tamoxifen Citrate or Exemestane on Clinical Trial IBCSG 24-02
ClinicalTrials.gov study NCT00975676. IPD Sharing: NO. Countries: 8. Publications: 0.
Tamoxifen and Clomiphene Citrate in Mild Stimulation IVF
ClinicalTrials.gov study NCT02690870. IPD Sharing: YES. Countries: 0. Publications: 14.
4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
ClinicalTrials.gov study NCT00952731. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Evaluation the Treatment of Tamoxifen of Low/Intermediate Risk Bladder Tumors
ClinicalTrials.gov study NCT02197897. IPD Sharing: NO. Countries: 1. Publications: 0.
Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen
ClinicalTrials.gov study NCT00118157. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Treatment Effect of Tamoxifen on Patients With DMD
ClinicalTrials.gov study NCT02835079. IPD Sharing: Not stated. Countries: 0. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.